Companies Passage BIO, Inc.
Passage BIO CEO salary & total pay, FY2025: $1.5M
Passage BIO (PASG) CEO salary, fiscal 2025: William Chou was paid a salary of $660,985 and $1,486,763 in total compensation. Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Passage BIO, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
William Chou's complete compensation dossier
A PDF and a CSV sent to your email: William Chou's pay in every fiscal year Passage BIO, Inc. reported it, line by line, with William Chou's equity grants and Passage BIO, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $1,448,545FY2023
- $1,636,770FY2024
- $1,486,763FY2025
CEO total pay was $1,486,763 in fiscal 2025, down from $1,636,770 in fiscal 2024.
FY2025: salary $660,985 · stock awards $234,040 · option awards $239,266
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| William Chou | $660,985 | — | $234,040 | $239,266 | $334,972 | — | $17,500 | $1,486,763 |
| President, Chief Executive Officer and Director | ||||||||
| Kathleen Borthwick | 450,627 | — | 117,020 | 85,440 | 181,252 | — | 17,500 | 851,839 |
| Chief Financial Officer | ||||||||
| Edgar Cale | 221,860 | — | 197,080 | 156,850 | 0 | — | 17,500 | 593,290 |
| General Counsel and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| William Chou | $1,486,763 | $1,636,770 | $1,448,545 | ↓ −150,007 |
| Kathleen Borthwick | 851,839 | 861,698 | — | ↓ −9,859 |
| Edgar Cale | 593,290 | 881,920 | 949,726 | ↓ −288,630 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company seeks to design and implement a competitive executive compensation program that combines both cash and incentive elements based on annual performance objectives and long-term equity elements that will be flexible and complementary to meet our compensation objectives. The Compensation Committee regularly reviews all compensation components to ensure they are consistent with short-term and long-term goals.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Edgar Cale | Option | 13,712 | — | 161.37 | — |
| Edgar Cale | Option | 4,986 | — | 360 | — |
| Edgar Cale | Option | 8,549 | — | 437 | — |
| Edgar Cale | Option | 5,299 | — | 90.4 | — |
| Edgar Cale | Option | 5,000 | — | 36 | — |
| Edgar Cale | Option | 5,299 | — | 45.8 | — |
| Edgar Cale | Option | 8,749 | — | 21.6 | — |
| Edgar Cale | Option | 10,149 | — | 30 | — |
| Edgar Cale | Option | 2,499 | — | 14 | — |
| Edgar Cale | Option | 13,918 | — | 7.74 | — |
| Kathleen Borthwick | Option | 1,893 | 856 | 21.6 | — |
| Kathleen Borthwick | Option | 604 | 395 | 17.55 | — |
| Kathleen Borthwick | Option | 4,966 | 6,384 | 30 | — |
| Kathleen Borthwick | RSU | — | 10,000 | — | 118,000 |
| Kathleen Borthwick | Option | 2,610 | 11,308 | 7.74 | — |
| Kathleen Borthwick | Option | 2,799 | — | 135 | — |
| Kathleen Borthwick | Option | 1,043 | — | 45.8 | — |
| William Chou | Option | 8,695 | 2,280 | 26.4 | — |
| William Chou | Option | 26,344 | 6,930 | 26.4 | — |
| William Chou | Option | 20,922 | 9,507 | 21.6 | — |
| William Chou | Option | 12,579 | 16,170 | 30 | — |
| William Chou | RSU | — | 20,000 | — | 236,000 |
| William Chou | Option | 7,308 | 31,668 | 7.74 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Maxine Gowen, Ph.DIndependent · Board Chair · Compensation · Nominating/Governance · Audit | $83,500 | — | $55,000 | — | $0 | $138,500 |
| Sandip KapadiaIndependent · Audit | 55,000 | — | 55,000 | — | 0 | 110,000 |
| Athena Countouriotis, M.DIndependent · Audit · Compensation (Chair) | 54,181 | — | 55,000 | — | 0 | 109,181 |
| Derrell Porter, M.DIndependent · Compensation · Nominating/Governance · Audit | 49,500 | — | 55,000 | — | 0 | 104,500 |
| Dolan Sondhi, Ph.DIndependent · Nominating/Governance | 44,000 | — | 55,000 | — | 0 | 99,000 |
| Saqib IslamNot independent · Departed during FY | 35,340 | — | 55,000 | — | 0 | 90,340 |
| Thomas KassbergIndependent · Audit | 47,500 | — | 39,176 | — | 0 | 86,676 |
| William Chou, M.DEmployee director · Nominating/Governance | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $55,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $369,021 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $369,021 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Passage BIO as a peer
Companies that benchmark against PASG
The list of companies that name PASG as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Aligos Therapeutics, Inc. | 2025 | Lawrence Blatt | $651,718 | $0 | $3,014,995 | $371,479 | $4,057,234 |
| 2 | Jasper Therapeutics, Inc. | 2025 | Ronald Martell | 727,272 | 0 | 1,766,827 | 0 | 2,494,099 |
| 3 | ALX Oncology Holdings Inc. | 2025 | Jason Lettmann | 724,500 | 0 | 1,447,488 | 298,856 | 2,470,844 |
| 4 | Century Therapeutics, Inc. | 2025 | Brent Pfeiffenberger | 640,625 | 1,869,609 | 222,681 | 317,109 | 2,381,022 |
| 5 | Precision BioSciences, Inc. | 2025 | Michael Amoroso | 650,875 | 1,025,086 | 0 | 0 | 2,189,467 |
| 6 | Passage BIO, Inc. | 2025 | William Chou | 660,985 | 234,040 | 239,266 | 334,972 | 1,486,763 |
| 7 | AN2 Therapeutics, Inc. | 2025 | Eric Easom | 603,750 | 164,133 | 275,539 | 332,063 | 1,382,985 |
| 8 | Kezar Life Sciences, Inc. | 2025 | Christopher Kirk | 618,000 | 0 | 588,828 | 0 | 1,220,828 |
| 9 | Actinium Pharmaceuticals, Inc. | 2025 | Sandesh Seth | 762,320 | 0 | 0 | 0 | 1,187,320 |
| 10 | Lisata Therapeutics, Inc. | 2025 | David Mazzo | 711,729 | 307,800 | 104,080 | 0 | 1,147,359 |
| 11 | NextCure, Inc. | 2025 | Michael Richman | 609,258 | 0 | 189,170 | 122,000 | 941,692 |
| 12 | Kala BIO, Inc. | 2025 | Mark Iwicki | 111,866 | 166,413 | 627,467 | 0 | 906,642 |
| 13 | PDS Biotechnology Corporation | 2025 | Frank Bedu-Addo | 615,322 | 0 | 193,500 | 0 | 828,307 |
| 14 | Celularity Inc. | 2025 | Robert Hariri | 600,000 | 0 | 0 | 0 | 650,651 |
| — | Lantern Pharma Inc. | — | — | — | — | — | — | not in coverage universe |
| — | BioAtla, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Xilio Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Immunic, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Passage BIO, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Actinium Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | StreeterWyatt Analytics LLC |
| Aligos Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Radford |
| ALX Oncology Holdings Inc. | not disclosed | not disclosed | not disclosed | Compensia |
| AN2 Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| BioAtla, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Celularity Inc. | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | not disclosed |
| Century Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Immunic, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Jasper Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | not disclosed |
| Kala BIO, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Kezar Life Sciences, Inc. | not disclosed | Option 100 | not disclosed | not disclosed |
| Lantern Pharma Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Lisata Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford/AON |
| NextCure, Inc. | not disclosed | Option 100 | not disclosed | Pearl Meyer & Partners, LLC |
| PDS Biotechnology Corporation | not disclosed | not disclosed | not disclosed | not disclosed |
| Precision BioSciences, Inc. | 115% | RSU 100 | not disclosed | Aon |
| Xilio Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-19 | 1,452,505 | 36,352 | 1,356 | 97.56% | Passed |
| 2025 | 2025-05-28 | — | — | — | — | — |
| 2024 | — | — | — | — | — | — |
| 2022 | — | — | — | — | — | — |
| 2021 | 2021-05-27 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2022 | — | —a |
| 2024 | — | —b |
| 2026 | 2026-05-19 | 97.56%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Advisory approval of this proposal requires the affirmative vote of the holders of a majority of the voting power of the shares present online at the virtual Annual Meeting or represented by proxy at the Annual Meeting and voting affirmatively or negatively (excluding abstentions and broker non-votes) on this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Sandip Kapadia | Director | 2026-05-19 | A | 10,539 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Athena Countouriotis | Director | 2026-05-19 | A | 10,539 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Maxine Gowen | Director | 2026-05-19 | A | 10,539 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Kassberg | Director | 2026-05-19 | A | 10,539 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Derrell Porter | Director | 2026-05-19 | A | 10,539 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dolan Sondhi | Director | 2026-05-19 | A | 10,539 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lynx1 Capital Management LP | Greater-than-10% holder | 2026-06-25 | A | 50,055 | 4 | 206,101 | Common, indirect | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (37 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, William Chou. DEF 14A, filed 2026-04-07. Section “Executive Compensation”. As printed: 1,486,763. View filing ↗
- Section 01, Kathleen Borthwick. DEF 14A, filed 2026-04-07. Section “Executive Compensation”. As printed: 851,839. View filing ↗
- Section 01, Edgar Cale. DEF 14A, filed 2026-04-07. Section “Executive Compensation”. As printed: 593,290. View filing ↗
- Section 08, Maxine Gowen, Ph.D. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 138,500. View filing ↗
- Section 08, Sandip Kapadia. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 110,000. View filing ↗
- Section 08, Athena Countouriotis, M.D. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 109,181. View filing ↗
- Section 08, Derrell Porter, M.D. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 104,500. View filing ↗
- Section 08, Dolan Sondhi, Ph.D. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 99,000. View filing ↗
- Section 08, Saqib Islam. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 90,340. View filing ↗
- Section 08, Thomas Kassberg. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 86,676. View filing ↗
- Section 08, William Chou, M.D. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Sandip Kapadia 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Athena Countouriotis 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Maxine Gowen 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Kassberg 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Derrell Porter 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dolan Sondhi 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynx1 Capital Management LP 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-03-03. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-10-24. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-26. Item 5.07 · say-on-pay result. As reported: 97.56% (votes for as printed: 1,452,505). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 369,021 + equity 0 + all other 0 = 369,021, summed across the director compensation table rows.
- Aligos Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Aligos Therapeutics, Inc.'s own proxy. As printed: 4,057,234. View filing ↗
- Jasper Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-06-15. CEO total compensation as printed in Jasper Therapeutics, Inc.'s own proxy. As printed: 2,494,099. View filing ↗
- ALX Oncology Holdings Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in ALX Oncology Holdings Inc.'s own proxy. As printed: 2,470,844. View filing ↗
- Century Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Century Therapeutics, Inc.'s own proxy. As printed: 2,381,022. View filing ↗
- Precision BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Precision BioSciences, Inc.'s own proxy. As printed: 2,189,467. View filing ↗
- Passage BIO, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Passage BIO, Inc.'s own proxy. As printed: 1,486,763. View filing ↗
- AN2 Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in AN2 Therapeutics, Inc.'s own proxy. As printed: 1,382,985. View filing ↗
- Kezar Life Sciences, Inc., Section 10b CEO total. 10-K/A, filed 2026-04-30. CEO total compensation as printed in Kezar Life Sciences, Inc.'s own proxy. As printed: 1,220,828. View filing ↗
- Actinium Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-16. CEO total compensation as printed in Actinium Pharmaceuticals, Inc.'s own proxy. As printed: 1,187,320. View filing ↗
- Lisata Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-19. CEO total compensation as printed in Lisata Therapeutics, Inc.'s own proxy. As printed: 1,147,359. View filing ↗
- NextCure, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in NextCure, Inc.'s own proxy. As printed: 941,692. View filing ↗
- Kala BIO, Inc., Section 10b CEO total. DEF 14A, filed 2026-09-24. CEO total compensation as printed in Kala BIO, Inc.'s own proxy. As printed: 906,642. View filing ↗
- PDS Biotechnology Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-26. CEO total compensation as printed in PDS Biotechnology Corporation's own proxy. As printed: 828,307. View filing ↗
- Celularity Inc., Section 10b CEO total. DEF 14A, filed 2026-11-10. CEO total compensation as printed in Celularity Inc.'s own proxy. As printed: 650,651. View filing ↗